You can help make a drug to treat GvHD available to patients in Canada.

AAMAC, along with an alliance of 8 other blood cancer organizations, are preparing patient input submissions for the Canadian Agency for Drugs and Technologies (CADTH) and Institut national d’excellence en santé et services sociaux (INESSS). The submissions will help them make recommendations to the provinces and territories regarding funding for ruxolitinib (Jakavi), a new treatment for GvHD.

We invite all patients world-wide who have received an allogeneic stem cell transplant to share their experience regarding graft-versus-host disease.

You do not need to live in Canada to complete this survey.

The survey will be open until midnight Pacific Time on Saturday, May 15, 2021 and should only take 25 minutes of your time.